Lumiera Health Past Earnings Performance
Past criteria checks 0/6
Lumiera Health has been growing earnings at an average annual rate of 3%, while the Pharmaceuticals industry saw earnings growing at 43.8% annually. Revenues have been declining at an average rate of 30.8% per year.
Key information
3.0%
Earnings growth rate
22.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -30.8% |
| Return on equity | n/a |
| Net Margin | -398.2% |
| Last Earnings Update | 31 Aug 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How Lumiera Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 23 | 0 | -2 | 1 | 0 |
| 31 May 23 | 0 | -2 | 1 | 0 |
| 28 Feb 23 | 1 | -2 | 1 | 0 |
| 30 Nov 22 | 1 | -3 | 1 | 0 |
| 31 Aug 22 | 1 | -2 | 2 | 0 |
| 31 May 22 | 1 | -1 | 2 | 0 |
| 28 Feb 22 | 1 | -1 | 2 | 0 |
| 30 Nov 21 | 1 | -1 | 2 | 0 |
| 31 Aug 21 | 0 | -2 | 2 | 0 |
| 31 May 21 | 1 | -2 | 1 | 0 |
| 28 Feb 21 | 0 | -3 | 1 | 0 |
| 30 Nov 20 | 1 | -2 | 1 | 0 |
| 31 Aug 20 | 0 | -2 | 1 | 0 |
| 31 May 20 | 0 | -2 | 2 | 0 |
| 29 Feb 20 | 0 | -2 | 2 | 0 |
| 30 Nov 19 | 0 | -2 | 2 | 0 |
| 31 Aug 19 | 1 | -2 | 1 | 0 |
| 31 May 19 | 1 | -2 | 1 | 0 |
| 28 Feb 19 | 1 | -2 | 1 | 0 |
| 30 Nov 18 | 1 | -1 | 1 | 0 |
| 31 Aug 18 | 1 | 0 | 1 | 0 |
| 31 May 18 | 0 | 0 | 1 | 0 |
| 28 Feb 18 | 0 | 0 | 0 | 0 |
| 30 Nov 17 | 0 | 0 | 0 | 0 |
| 30 Nov 16 | 0 | 0 | 0 | 0 |
Quality Earnings: NHP.H is currently unprofitable.
Growing Profit Margin: NHP.H is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NHP.H's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NHP.H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NHP.H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Return on Equity
High ROE: NHP.H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.